Cinryze, Ruconest(conestat alfa)
Ruconest (conestat alfa) is a protein pharmaceutical. Conestat alfa was first approved as Ruconest on 2010-10-28. It has been approved in Europe to treat hereditary angioedemas.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Berinert, Cinryze, Haegarda, Ruconest
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
C1 esterase inhibitor (human)
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Berinert | C1 Esterase Inhibitor (Human) | CSL Behring | A-125287 RX | 2009-10-09 | 1 products |
| Cinryze | C1 Esterase Inhibitor (Human) | Takeda | A-125267 RX | 2008-10-10 | 1 products |
C1 esterase inhibitor (recombinant)
C1 esterase inhibitor subcutaneous (human)
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Haegarda | C1 Esterase Inhibitor Subcutaneous (Human) | CSL Behring | A-125606 RX | 2017-06-22 | 2 products |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
92 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Angioedema | D000799 | EFO_0005532 | T78.3 | 6 | 20 | 27 | 3 | 14 | 62 |
| Hereditary angioedemas | D054179 | EFO_0004131 | — | 7 | 21 | 23 | 4 | 13 | 60 |
| Hereditary angioedema types i and ii | D056829 | — | — | 2 | 5 | 3 | 1 | 1 | 10 |
| Covid-19 | D000086382 | — | — | — | 3 | — | 1 | — | 4 |
| Fatigue | D005221 | HP_0012378 | R53.83 | — | — | — | 1 | — | 1 |
| Chronic fatigue syndrome | D015673 | EFO_0004540 | G93.31 | — | — | — | 1 | — | 1 |
| Common variable immunodeficiency | D017074 | EFO_0000367 | D83 | — | — | — | 1 | — | 1 |
| Asthma | D001249 | EFO_0000270 | J45 | — | — | — | 1 | — | 1 |
| Prodromal symptoms | D062706 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inborn genetic diseases | D030342 | EFO_0000508 | — | — | 3 | 2 | — | — | 4 |
| Wounds and injuries | D014947 | — | T14.8 | — | 2 | 1 | — | — | 3 |
| Inflammation | D007249 | MP_0001845 | — | — | — | 2 | — | 1 | 3 |
| Sepsis | D018805 | HP_0100806 | A41.9 | — | — | 2 | — | — | 2 |
| Endotoxemia | D019446 | — | — | — | — | 1 | — | 1 | 2 |
| Multiple organ failure | D009102 | EFO_1001373 | — | — | — | 1 | — | 1 | 2 |
| Innate immunity | D007113 | — | — | — | — | 1 | — | — | 1 |
| Hip fractures | D006620 | EFO_0003964 | S72.00 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal insufficiency | D051437 | HP_0000083 | N19 | 3 | 1 | — | — | — | 3 |
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | 3 | — | — | — | 3 |
| Ischemia | D007511 | EFO_0000556 | — | — | 2 | — | — | — | 2 |
| Reperfusion injury | D015427 | — | — | 1 | 2 | — | — | — | 2 |
| Kidney transplantation | D016030 | — | — | 1 | 2 | — | — | — | 2 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.9 | 2 | 2 | — | — | — | 2 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 2 | 2 | — | — | — | 2 |
| Delayed graft function | D051799 | — | — | 2 | 1 | — | — | — | 2 |
| Graft rejection | D006084 | — | — | — | 2 | — | — | — | 2 |
| Ischemic stroke | D000083242 | — | — | 1 | 1 | — | — | — | 2 |
Show 21 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuromyelitis optica | D009471 | EFO_0004256 | G36.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Immunologic tests | D007159 | — | — | — | — | — | — | 1 | 1 |
| Graft vs host disease | D006086 | — | D89.81 | — | — | — | — | 1 | 1 |
| Systemic mastocytosis | D034721 | — | C96.21 | — | — | — | — | 1 | 1 |
| Urticaria | D014581 | EFO_0005531 | L50 | — | — | — | — | 1 | 1 |
| Mastocytosis | D008415 | — | D47.09 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Conestat alfa |
| INN | conestat alfa |
| Description | Ruconest (conestat alfa) is a protein pharmaceutical. Conestat alfa was first approved as Ruconest on 2010-10-28. It has been approved in Europe to treat hereditary angioedemas. |
| Classification | Protein |
| Drug class | enzyme inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108350 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB06404 |
| UNII ID | 5QS67N4551 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Ruconest – Pharming
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,688 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,076 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use